New drug may keep stage III lung cancer in check after chemoradiation
NCT ID NCT07204548
First seen Oct 31, 2025 · Last updated Jun 15, 2026 · Updated 34 times
Summary
This study tests a drug called ivonescimab given for one year after standard chemoradiation in people with stage III lung cancer that cannot be removed by surgery. The goal is to see if it can delay cancer growth. About 63 adults aged 18–75 who have not gotten worse after chemoradiation will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (STAGE III) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Li-Kun Chen
Guangzhou, Guangzhou, 510006, China
Conditions
Explore the condition pages connected to this study.